OTCMKTS:AKAOQ

Achaogen Competitors

$0.03
0.00 (-0.37 %)
(As of 04/14/2021 02:51 PM ET)
Add
Compare
Today's Range
$0.02
Now: $0.03
$0.03
50-Day Range
$0.02
MA: $0.03
$0.04
52-Week Range
$0.00
Now: $0.03
$0.05
Volume20,773 shs
Average Volume248,455 shs
Market Capitalization$1.30 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.84

Competitors

Achaogen (OTCMKTS:AKAOQ) Vs. IPCIF, BCTXF, FWDG, ABMC, AMBS, and AKRXQ

Should you be buying AKAOQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Achaogen, including Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), FutureWorld (FWDG), American Bio Medica (ABMC), Amarantus BioScience (AMBS), and Akorn (AKRXQ).

Achaogen (OTCMKTS:AKAOQ) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Achaogen has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Achaogen and Intellipharmaceutics International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achaogen0000N/A
Intellipharmaceutics International0000N/A

Valuation and Earnings

This table compares Achaogen and Intellipharmaceutics International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A
Intellipharmaceutics International$3.48 million1.57$-8,090,000.00N/AN/A

Intellipharmaceutics International has lower revenue, but higher earnings than Achaogen.

Insider and Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Achaogen and Intellipharmaceutics International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AchaogenN/AN/AN/A
Intellipharmaceutics International-232.11%N/A-81.71%

Summary

Achaogen beats Intellipharmaceutics International on 5 of the 8 factors compared between the two stocks.

Achaogen (OTCMKTS:AKAOQ) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Achaogen and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AchaogenN/AN/AN/A
BriaCell TherapeuticsN/AN/A-786.77%

Insider & Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Achaogen and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achaogen0000N/A
BriaCell Therapeutics0000N/A

Valuation & Earnings

This table compares Achaogen and BriaCell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A

BriaCell Therapeutics has lower revenue, but higher earnings than Achaogen.

Volatility & Risk

Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Achaogen (OTCMKTS:AKAOQ) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Achaogen and FutureWorld's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AchaogenN/AN/AN/A
FutureWorldN/AN/AN/A

Insider & Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Achaogen and FutureWorld, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achaogen0000N/A
FutureWorld0000N/A

Valuation & Earnings

This table compares Achaogen and FutureWorld's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A
FutureWorldN/AN/AN/AN/AN/A

FutureWorld has lower revenue, but higher earnings than Achaogen.

Volatility & Risk

Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. Comparatively, FutureWorld has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Summary

Achaogen beats FutureWorld on 3 of the 4 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

American Bio Medica has a beta of -1.45, meaning that its stock price is 245% less volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for American Bio Medica and Achaogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
Achaogen0000N/A

Earnings & Valuation

This table compares American Bio Medica and Achaogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million1.18$-680,000.00N/AN/A
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A

American Bio Medica has higher earnings, but lower revenue than Achaogen.

Insider & Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 13.0% of American Bio Medica shares are owned by company insiders. Comparatively, 7.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares American Bio Medica and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
AchaogenN/AN/AN/A

Summary

Achaogen beats American Bio Medica on 5 of the 8 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

Amarantus BioScience has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Achaogen has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Profitability

This table compares Amarantus BioScience and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarantus BioScienceN/AN/AN/A
AchaogenN/AN/AN/A

Earnings & Valuation

This table compares Amarantus BioScience and Achaogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarantus BioScienceN/AN/AN/AN/AN/A
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A

Amarantus BioScience has higher earnings, but lower revenue than Achaogen.

Analyst Recommendations

This is a summary of recent ratings for Amarantus BioScience and Achaogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarantus BioScience0000N/A
Achaogen0000N/A

Insider & Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. Comparatively, 0.0% of Achaogen shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by company insiders. Comparatively, 7.8% of Achaogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Amarantus BioScience beats Achaogen on 2 of the 3 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Risk & Volatility

Akorn has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, meaning that its share price is 184% less volatile than the S&P 500.

Profitability

This table compares Akorn and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
AchaogenN/AN/AN/A

Valuation & Earnings

This table compares Akorn and Achaogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A

Achaogen has lower revenue, but higher earnings than Akorn.

Analyst Ratings

This is a summary of recent recommendations and price targets for Akorn and Achaogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Achaogen0000N/A

Insider and Institutional Ownership

0.1% of Akorn shares are held by institutional investors. Comparatively, 0.0% of Achaogen shares are held by institutional investors. 3.9% of Akorn shares are held by company insiders. Comparatively, 7.8% of Achaogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Achaogen beats Akorn on 6 of the 9 factors compared between the two stocks.


Achaogen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23-4.8%$5.19 million$3.48 million-1.92News Coverage
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-16.7%$4.56 millionN/A0.00Gap Down
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11-4.3%$4.49 million$3.65 million0.00Decrease in Short Interest
AMBS
Amarantus BioScience
0.0$0.01-1.8%$4.13 millionN/A0.00Increase in Short Interest
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
RSPI
RespireRx Pharmaceuticals
0.5$0.04-5.6%$3.00 millionN/A-0.09
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17-15.2%$2.94 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.02-1.3%$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-2.6%$2.22 million$20,000.00-0.98
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48-6.2%$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09-0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-21.6%$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-5.9%$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.00-5.0%$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25-79.4%$1.12 millionN/A-2.76Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-19.7%$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02-10.4%$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.8%$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03-0.4%$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-12.9%$928,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08-0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-125.0%$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02-36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00-20.0%$678,000.00N/A0.00Increase in Short Interest
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15-1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17-0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07-0.0%$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-17.6%$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03-0.0%$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09-5.9%$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02-0.0%$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-13.2%$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.05-26.2%$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09-13.6%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50-0.0%$0.00N/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.